Zhitong Finance App News, Eddy Pharmaceutical (688488.SH) issued an announcement. Recently, the company and its wholly-owned subsidiaries Chengdu Eddy Pharmaceutical Technology Co., Ltd. and Nanjing Eddy Pharmaceutical Technology Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing that the company is developing a Class 1 new drug ADC118 to carry out phase III clinical trials in the field of anti-AIDS.

The clinical study of ADC118 tablets to be carried out by the company after obtaining the notice is a randomized, double-blind, double-simulation phase III trial with BIC/FTC/TAF (BIC/FTC/TAF, trade name: Bitovir, Biktarvy) as a positive control to evaluate its efficacy and safety in treating HIV-1 infected adults. Furthermore, ADC118 tablets have completed bioequivalence (BE) studies among Chinese health participants, and complete human pharmacokinetics data have been obtained. The relevant research results have laid a good foundation for the development of phase III clinical trials of this product.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.